The combinations evaluated will be:~EOS-448 combined with pembrolizumab, an anti-PD-1 antibody~EOS-448 combined with inupadenant an investigational adenosine A2A receptor antagonist~EOS-448 combined with dostarlimab an anti-PD-1 antibody~inupadenant combined with dostarlimab~EOS-448 combined with inupadenant and dostarlimab~EOS-448 combined with dostarlimab and standard of care chemotherapies in participants with NSCLC
This is a multicenter, open-label, phase I/II basket study, evaluating the safety, tolerability, RP2D, pharmacokinetics, pharmacodynamics and antitumor activity of EOS-448 (also known as GSK4428859A) combined with standard of care and/or with investigational therapies in participants with advanced solid tumors.